PMS2 and endometrial cancer: In one recent study from the ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) group, patients in the MMR-deficient subgroup (defined as those displaying loss of PMS2 and MSH6) had relatively poor outcomes [24], although in general, the prognostic significance of DNA MMR protein deficiency in endometrial cancer is still the subject of debate [45, 46].